• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
Mosquito icon

Dengue

Symptoms, transmission, and current treatments for dengue

Home > Diseases
Mosquito icon

Dengue

Symptoms, transmission, and current treatments for dengue

  • Overview
  • Facts
  • Projects & achievements
  • Target product profile

What is dengue?

Dengue is the most widely distributed mosquito-borne viral disease in the world. Driven by climate change, rapid urbanization, and increased population mobility, it continues to spread rapidly. Outbreaks are usually seasonal, peaking during and after rainy seasons. The World Health Organization ranks dengue among the top ten threats to public health.

Caused by a virus that is mostly transmitted by the bite of Aedes aegypti mosquitoes, dengue symptoms can include fever, nausea, vomiting, rashes, fatigue, and intense eye, muscle, joint, and bone pain. For some, dengue infection can become severe, with complications such as bleeding and plasma leakage that can lead to shock, organ dysfunction, and death. Pregnant women, children, older adults, and people with comorbidities are most at risk.

There are four closely related dengue viruses, called dengue serotypes. Although recovery from infection generally provides immunity from the same dengue serotype, it also increases the risk of severe dengue if people are later infected with a different serotype.

What is the impact of dengue?

  • • More than half of the world’s population lives in areas at risk of dengue
  • • Endemic in over 100 countries around the world, with 86% of cases reported in the Americas
  • • 100-400 million estimated infections each year
  • • 14.4 million cases reported to WHO in 2024 – the highest ever recorded
  • • 11,200 deaths reported in 2024
  • • Puts immense pressure on health systems during outbreaks
  • • Most dengue infections go unreported as they are asymptomatic, mild and self-managed, or misdiagnosed
  •  
Dengue Map frp, WHO 2025

What are current treatments for dengue?

There are no specific antiviral drugs to treat dengue infection, or to prevent mild cases from progressing to severe disease.   

Acetaminophen or paracetamol can be taken to control muscle aches, pains, and fever. Non-steroidal anti-inflammatory drugs such as ibuprofen and aspirin should be avoided.

Hospitalized dengue patients must be closely observed, and their fluid intake carefully managed, according to strict guidelines. In countries where early detection and specialized medical care for severe dengue is available, the fatality rate is below 1%.

Vaccines are an important component of dengue prevention, but their indications, availability, and recommendations vary by country and population. Qdenga (TAK-003) is currently used in several countries, particularly in settings with high dengue transmission. Additional vaccines are also progressing through national regulatory and implementation pathways. As live-attenuated vaccines, however, they are not currently recommended for high-risk groups such as pregnant women, older adults, and infants. Vaccination therefore complements, rather than replaces, vector control, surveillance, early diagnosis, and appropriate clinical management.

What new treatments for dengue are needed?

Effective treatments that can prevent mild
cases of dengue from becoming severe are urgently needed. Patient care – even
for serious cases – remains purely supportive, placing burdens on health
systems that can become rapidly overwhelmed during outbreaks.

What dengue treatments are we working on?

Together with partners in the Dengue Alliance, we are actively searching for new treatments and have advanced two candidates to Phase II and III clinical trials. We aim to complete development of at least one affordable and accessible dengue treatment solution, advance the pre-clinical development of both host-directed therapies (HDTs) and antiviral candidates, evaluate promising biomarkers that can predict development of severe dengue, and help close the epidemiological data gap on the burden of dengue in Africa. 

Find out about our work developing treatments for dengue.

How do you get dengue?

  • Insect bites: the virus that causes dengue can be transmitted by the bite of infected female Aedes mosquitoes
  • Mother-to-child: transmission from mother to child during pregnancy or childbirth is possible
  • Rare cases of transmission via blood products, organ donation, and transfusions have occurred

What are the symptoms of dengue?

Dengue can have no symptoms or cause only mild illness with flu-like symptoms. Moderate dengue infection has symptoms including:

  • high fever (40°C/104°F)
  • severe headache
  • pain behind the eyes
  • nausea
  • vomiting
  • swollen glands
  • rash
  • muscle, joint, or bone pains so severe that dengue is sometimes referred to as ‘breakbone fever’

Severe dengue occurs when blood vessels become damaged and leak, and the number of platelets (cells that form clots) drops. As a result, severe dengue can cause shock, internal bleeding, bleeding gums or nose, organ failure, and death. The symptoms of severe dengue include:

  • severe abdominal pain
  • persistent vomiting
  • rapid breathing
  • bleeding gums or nose
  • fatigue
  • restlessness
  • liver enlargement
  • blood in vomit or stool

How is dengue diagnosed?

Dengue can be diagnosed using laboratory or rapid diagnostic tests. During the first days of illness, molecular tests such as RT-PCR can detect dengue virus RNA, while NS1 antigen tests detect a viral protein circulating in the blood. After approximately five days of illness, antibody tests become increasingly useful for identifying a recent infection. Test performance varies by assay, timing of testing, and epidemiological context, and access to reliable diagnostics remains limited in many dengue-endemic settings. Also under development are biomarker tests that could identify individuals at higher risk of developing complications, a much-needed resource that would be useful for treatment optimization during outbreaks.

More information

  • WHO factsheet 

Last updated: Ocotber 2026

‘Treating a feverish planet: The Dengue Alliance’

Recent years have seen an alarming upsurge in dengue outbreaks all over the world. This short film takes us to Brazil, Sri Lanka, and Thailand to show the devastating impact dengue outbreaks are having across the world.  

watch film

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We conducted the world’s first trial for an alternative to current treatments, which are toxic and difficult to administer

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Healthcare workers in a hospital

Pandemic preparedness and response

COVID-19 threw longstanding global health injustices into stark relief

We’re conducting research for new drugs before the next pandemic strikes and advocating for equitable innovation and access

Parasitic worms

Cause debilitating illness, social exclusion, and long-term disability

We’re working across multiple diseases to develop missing cures that can prevent lasting harm

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

Cryptococcal meningitis

Cutaneous leishmaniasis

Dengue

Hepatitis C

Mycetoma

Paediatric HIV

Pandemic preparedness and response

Parasitic worms

Sleeping sickness

Visceral leishmaniasis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license